Please assess the completion status of the following clinical trial:

Trial Title: Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Pre-randomization Inclusion Criteria:~* Provide written informed consent before initiation of any study-related procedures.~* Be at least 18 years of age~* Be scheduled for cardiac surgery (including Coronary Artery Bypass Grafting \[CABG\], Off Pump Coronary Artery Bypass \[OPCAB\], Minimally Invasive Direct Coronary Artery Bypass \[MIDCAB\] surgery, and/or valve replacement/repair procedures)~Pre-randomization Exclusion Criteria:~* Women of child-bearing potential (unless they have a negative pregnancy test)~* Recent cerebrovascular accident (within 3 months before randomization)~* Known intolerance to calcium channel blockers~* Allergy to soybean oil or egg lecithin (components of the lipid vehicle)~* Pre-existing left bundle branch block or permanent ventricular pacing~* Any other disease or condition, which, in the judgment of the investigator would place a patient at undue risk by being enrolled in the trial.~* Participation in another therapeutic drug or therapeutic device trial within 30 days of starting study~Post-randomization Inclusion Criteria:~* Expected to survive beyond 24 hours post-surgical procedure~* No surgical complications or conditions, present or anticipated, that preclude them from inclusion in a double blind, placebo-controlled study~* Determined to be hypertensive (SBP \> 140 mm Hg) within 4 hours of arrival in a postoperative setting~* It is the investigator's intent to lower the patient's SBP by a minimum of 15% from its baseline value

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clevidipine (Type: EXPERIMENTAL): Clevidipine was administered in a blinded fashion intravenously, starting with an infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr), titrating upward, as tolerated by the patient, in doubling increments approximately every 90 seconds up to an infusion rate of 3.2 μg/kg/min (16 mg/hr) to achieve the desired blood pressure-lowering effect. Up-titration to infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing the infusion rate in serial increments of 1.5 μg/kg/min, up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
- placebo (Type: PLACEBO_COMPARATOR): Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete